

Supplementary Table 1: Hepatitis C virus genotype 3 proportion by province

Region	Province	Hepatitis C virus infection (n)	Genotype 3 (n, %)	Subtype 3a (n)	Subtype 3b (n)
East	Shandong	40	1 (2.5)	1	0
	Jiangsu	54	2 (3.7)	1	0
	Shanghai	54	3 (5.6)	1	1
	Zhejiang	32	8 (25.0)	4	4
	Jiangxi	37	1 (2.7)	0	1
West	Sichuan	21	0	0	0
	Chongqing	27	7 (25.9)	1	5
	Shaanxi	40	1 (2.5)	1	0
	Gansu	58	2 (3.4)	1	1
	Ningxia	27	12 (44.4)	8	3
	Shanxi	36	0	0	0
South	Fujian	11	2 (18.2)	1	1
	Guangdong	64	7 (10.9)	3	4
	Guangxi	40	4 (10.0)	1	3
	Yunnan	40	26 (65.0)	8	18
North	Beijing	92	6 (6.5)	1	5
	Liaoning	34	3 (8.8)	1	2
	Jilin	34	1 (2.9)	1	0
	Heilongjiang	21	1 (4.8)	0	1
Central	Henan	120	0	0	0
	Anhui	18	0	0	0
	Hubei	68	2 (2.9)	1	1
	Hunan	29	2 (6.9)	0	2

Supplementary Table 2: Comparison of baseline demographic, disease parameters in patients included in follow-up phase (genotype 3 vs. genotype 1)

Parameter	Genotype 1 (n=304)	Genotype 3 (n=41)	P values
Male, <i>n</i> (%)	164 (53.9)	32 (78.0)	<0.001
Age (years), mean±SD	46.9±13.6	39.5±8.7	0.001
Duration of infection (years), median (Q1, Q3)	18.58 (15.67, 21.17)	12.42 (8.96, 17.81)	<0.001
Age at time of HCV infection (years), median (Q1, Q3)	29 (20, 40)	27 (21, 30)	0.254
Body mass index (kg/m ²), mean (SD)	23.62 (3.58)	22.47 (3.66)	0.056
HCV RNA (log ₁₀ IU/ml), mean (SD)	5.90 (0.86)	5.91 (0.94)	0.969
ALT (U/L), median (Q1, Q3)	52.2 (32.0, 86.1)	90.0 (51.0, 145.5)	<0.001
Total bilirubin (μmol/L), median (Q1, Q3)	15.05 (11.00, 21.63)	16.00 (11.40, 23.45)	0.349
Platelet (×10 ⁹ /L), mean±SD	154.2±72.2	165.7±56.1	0.327
Diagnosis at enrollment			0.357
Chronic hepatitis, <i>n</i> (%)	266 (87.5)	39 (95.1)	
Compensated cirrhosis, <i>n</i> (%)	21 (6.9)	1 (2.4)	
Decompensated cirrhosis, <i>n</i> (%)	17 (5.6)	1 (2.4)	
Fatty liver at enrollment, <i>n</i> (%)	31 (10.2)	8 (19.5)	0.077
Fasting glucose (mmol/L), median (Q1, Q3)	5.03 (4.6, 5.48)	4.93 (4.5, 5.4)	0.297
Diabetes, <i>n</i> (%)	20 (6.6)	3 (7.3)	0.859
HBsAg positive, <i>n</i> (%)	11 (3.6)	2 (4.9)	0.691

SD: Standard deviation; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen.

Supplementary Figure 1: Kaplan-Meier Curve for time from estimated infection to overall-disease-progression for treated/untreated HCV-GT3 patients

